Efficacy of antidepressants combined with intestinal flora regulators in the treatment of depression
10.3760/cma.j.cn341190-20221118-00924
- VernacularTitle:抗抑郁药联合肠道菌群调节剂治疗抑郁症疗效分析
- Author:
Yanbao KANG
1
;
Longyou ZHAO
Author Information
1. 丽水市第二人民医院五病区，丽水 323000
- Keywords:
Depressive disorder;
Antidepressive agents;
Depression;
Anxiety;
Sleep;
Quality of life;
Interleukin-6;
Tumor necrosis factor-alpha
- From:
Chinese Journal of Primary Medicine and Pharmacy
2024;31(8):1144-1148
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical efficacy of antidepressants combined with intestinal flora regulators in patients with depression.Methods:The clinical data of 92 patients with depression admitted to the Second People's Hospital of Lishui from January 2019 to December 2021 were retrospectively analyzed. In the case-control study, the patients were divided into a control group ( n = 46) and an observation group ( n = 46) according to different treatment methods. The control group received treatment with escitalopram oxalate tablets, while the observation group received treatment with escitalopram oxalate tablets and bifidobacterium triple viable preparation. Both groups were treated for 2 months. The degrees of depression and anxiety, sleep quality, quality of life, levels of inflammatory factors, and the incidence of adverse reactions were compared between the two groups. Results:After 2 months of treatment, the scores of Hamilton Depression Scale and Hamilton Anxiety Scale in the observation group were (16.49 ± 2.96) points and (7.58 ± 1.66) points, respectively, which were significantly lower than those in the control group [(18.51 ± 3.13) points and (9.31 ± 2.01) points, t = 3.18, 4.50, P = 0.002, P < 0.001). After 4 and 8 weeks of treatment, the scores of Pittsburgh Sleep Quality Index in the observation group were (10.39 ± 2.30) points and (8.11 ± 1.82) points, respectively, which were significantly lower than those in the control group [(14.25 ± 2.66) points, (10.49 ± 2.07) points, t = 7.40, 5.86, both P < 0.001]. After 2 months of treatment, the total score of the Short Form-36 Health Survey in the observation group was (73.50 ± 9.16) points, which was significantly higher than that in the control group [(65.23 ± 7.29) points, t = 4.79, P < 0.001]. The levels of interleukin-6 and tumor necrosis factor-α in the observation group were (9.33 ± 2.72) ng/L and (16.71 ± 4.46) ng/L, respectively, which were significantly lower than those in the control group [(13.59 ± 4.05) ng/L, (23.20 ± 5.03) ng/L, t = 5.92, 6.55, both P < 0.001]. There was no significant difference in the incidence of adverse reactions between the two groups ( P > 0.05). Conclusion:The combined use of antidepressants and intestinal flora regulators can obviously reduce the severity of anxiety, depression, and insomnia in patients with depression, improve their quality of life, and lower the levels of inflammatory factors, with minimal adverse reactions and high safe.
